Ownership
Public
Employees
~746
Therapeutic Areas
OtherCardiovascular
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules (generic drugs)Medical devicesDietary supplements

Galenika General Information

Galenika is Serbia’s oldest pharmaceutical company with nearly eight decades of history. It manufactures over 250 products—primarily generic medicines but also dietary supplements and medical devices—serving Serbia as well as more than two dozen international markets across three continents. The company operates modern GMP-compliant facilities with significant annual production capacity for tablets/capsules/syrups/injectables/dental products. Since its acquisition by Brazil’s NC Group in late 2017 it has expanded into new EU markets through both organic growth and partnerships with global pharma companies such as Cantabria Labs and CromaPharma. Its product range covers most major therapeutic areas.

Contact Information

Primary Industry
Biotech
Corporate Office
Belgrade/Zemun,
Serbia

Drug Pipeline

No pipeline data available

For full access to Galenika's pipeline data

Book a demo

Key Partnerships

Cantabria Labs (Spain), CromaPharma (Austria), Pharmalife Research (Italy)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Galenika Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Galenika's complete valuation and funding history, request access »

Galenika Financial Metrics

Market Cap
$8417.4M
Total Revenue
$4767.1M
Enterprise Value
$7138.2M